New drug cocktail aims to fight tough esophageal cancer
NCT ID NCT07554456
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new combination of drugs (BL-B01D1 plus tislelizumab, with or without chemotherapy) as a first treatment for people with advanced esophageal cancer that cannot be removed by surgery. About 90 participants will be randomly assigned to receive either the new combo or standard chemotherapy plus immunotherapy. The main goal is to see if the new combo helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a targeted drug) combined with tislelizumab (an immunotherapy), with or without 5-fluorouracil (chemotherapy)
What this could lead to
If it works, this could offer a more effective first-line treatment for advanced esophageal cancer, potentially extending survival.
What could go wrong
This is an early-to-mid-stage trial with only 90 participants. The new drug combo may not work better than standard chemo, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact